Symptoms and General Pathology

All Conditions

Diseases and Abnormalities at or Before Birth

Neoplasms

Blood and Lymph Conditions

Heart and Blood Diseases

Rare Diseases

Syndrome

Congenital Abnormalities

Lymphangioma

Lymphatic Abnormalities

Thrombocytopenia

Hemangioendothelioma

Vascular Malformations

Hemangioma

Lymphangiectasis

Blood Platelet Disorders

Hematologic Diseases

Cytopenia

Neoplasms by Histologic Type

Lymphatic Diseases

Neoplasms, Vascular Tissue

Cardiovascular Abnormalities

Lymphatic Malformations

Microcystic Lymphatic Malformation

Kaposiform Hemangioendothelioma

Tufted Angioma

Lymphangiomatosis

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Sirolimus

Temsirolimus

MTOR Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Clotrimazole

Miconazole

Antifungal Agents

Immunosuppressive Agents

Immunologic Factors

sirolimus

Denise M Adams, MD

The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life.

Funding Source - FDA OOPD (Food and Drug Administration - Office of Orphan Products Development)

Patients with vascular anomalies (VA) have a spectrum of diseases that can be broadly classified into vascular tumors and malformations. Complicated vascular anomalies can cause disfigurement, chronic pain, and organ dysfunction with significant morbidity and mortality. Despite the severity of potential complications, we lack uniform guidelines for the treatment and response to treatment of children and young adults with these diseases. There are pre-clinical and clinical data supporting the essential regulatory function of the PI3K/Akt/mTOR pathway in vascular growth and organization, and suggest a therapeutic target for patients with complicated vascular anomalies. The overall goal of this trial is to objectively determine the effectiveness and safety of the mTOR inhibitor Rapamycin\* in the treatment of children and young adults diagnosed with complicated vascular anomalies. We propose a Phase 2 trial with the diagnostic, therapeutic and response criteria experimentally determined in this study used as a framework for future Phase 3 clinical trials.

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies

Children's Hospital Medical Center, Cincinnati

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies	NCT00975819	Kaposiform Hema... Tufted Angioma Capillary Venou... Venous Lymphati... Microcystic Lym... Mucocutaneous L... Capillary Lymph... PTEN Overgrowth... Lymphangiectasi...	sirolimus	- 31 Years	Children's Hospital Medical Center, Cincinnati
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies	NCT00975819	Kaposiform Hema... Tufted Angioma Capillary Venou... Venous Lymphati... Microcystic Lym... Mucocutaneous L... Capillary Lymph... PTEN Overgrowth... Lymphangiectasi...	sirolimus	- 31 Years	Children's Hospital Medical Center, Cincinnati

Spots Global Cancer Trial Database for mucocutaneous lymphangiomatosis and thrombocytopenia